Nicole Daley

Ms. Daley’s recent client representations include the following:

IPOs and Capital Markets Transactions

• Esperion Therapeutics in its $280 million 144A offering, $250 million “at-the-market” offering, and $225 million follow-on public offering.
• Bluebird bio in its $75 million private placement financing.
• AlloVir in its $317.7 million initial public offering and $100 million “at-the-market” offering. 
• Cerevel Therapeutics in its $350 million follow-on public offering.
• Kymera Therapeutics in its $257 million follow-on public offering.
• The underwriters in connection with Krystal Biotech’s over $250 million of follow-on public offerings.
• Achilles Therapeutics (United Kingdom) in its $175.5 initial public offering. 
• Deciphera Pharmaceuticals in its $175 million follow-on public offering and $200 million “at-the-market” offering.
• Karuna Therapeutics in its $100 million initial public offering, $250 million and $287.5 million follow-on public offerings, and $150 million “at-the-market” offering.
• BioDelivery Sciences International in its $60 million follow-on public offering. 
• Alnylam Pharmaceuticals in a $387.5 million follow-on public offering.

Private Company Financing Transactions

• Beta Bionics in its $63 million Series B2 financing and its $57 million Series C financing.
• Versanis Bio in its $70 million Series A financing.
• OrbiMed as co-lead investor in the $40 million Series A financing of Gennao Bio.
• Amylyx Pharmaceuticals in its $135 million Series C financing.
• Imvaq Therapeutics in its $15 million Series B Preferred Stock and convertible note financing. 
• Karuna Therapeutics in its $82 million Series B financing.
• Thrive Earlier Detection Corp. in its $110 million Series A financing.

Joint Ventures, M&A and Collaborations

• Vaccitech plc in its acquisition of Avidea Technologies, Inc. for approximately $40 million in cash and equity, plus potential payments upon achievement of milestones.
• Plug Power in a $1.5 billion equity investment in connection with its strategic partnership with South Korea-based SK Group.
• Thrive Earlier Detection Corp. in its acquisition by Exact Sciences Corporation for up to $2.15 billion.
• Unum Therapeutics in the sale of its BOXR (Bolt-on Chimeric Receptor) technology for approximately $11.5 million.
• Unum Therapeutics in its acquisition of Kiq LLC, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors, and concurrent PIPE investment to raise $104 million.
• Avadel Legacy Pharmaceuticals, a wholly-owned subsidiary of Avadel Pharmaceuticals (Ireland), in the sale of its hospital product assets for approximately $40 million.
• Alnylam Pharmaceuticals in a $100 million equity financing closed in connection with its $2 billion strategic financing collaboration with Blackstone.
• CRISPR Therapeutics in a series of transactions by which CRISPR acquired 100% of the partnership interests of Casebia Therapeutics.
• BeiGene in its $2.7 billion share sale as part of a global strategic collaboration with Amgen.
• BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion.
• Ultragenyx Pharmaceutical Inc. on its partnership with GeneTx Biotherapeutics LLC to develop GeneTx’s GTX-102.
• Arvinas, Inc. in its collaboration with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications.
• Alnylam Pharmaceuticals in a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron Pharmaceuticals.